ABOUT THE RESEARCHER

OVERVIEW

Genovese Lab

BACKGROUND

Dr. Pietro Genovese was recently a Project Leader at the San Raffaele Telethon Institute for Gene Therapy, having completed his post-doctoral fellowship in the laboratory of Molecular and Cell Biology of Gene Transfer with Professor Luigi Naldini in Italy. His current research focuses on gene-engineering technologies with a focus on hematopoietic stem cells and T cells. His future aim is to broaden his studies on pre-clinical development and to advance genetic engineering strategies with the aim to develop new treatment for human diseases, including cancer. At Dana-Farber/Boston Children's, Dr. Genovese joins the Gene Therapy Program in Pediatric Hematology/Oncology and the Program for Gene Therapy of Rare Diseases in the Department of Pediatrics (DOP). He has already had an impressively productive post-doctoral career with multiple publications, successful grant applications, and patents filed.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Editorial: Mutation-Specific Gene Editing for Blood Disorders. Front Genome Ed. 2021; 3:761771. View abstract
  2. Retrieval of vector integration sites from cell-free DNA. Nat Med. 2021 08; 27(8):1458-1470. View abstract
  3. BAR-Seq clonal tracking of gene-edited cells. Nat Protoc. 2021 06; 16(6):2991-3025. View abstract
  4. Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation. Front Genome Ed. 2021; 3:618378. View abstract
  5. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome. EMBO Mol Med. 2021 03 05; 13(3):e13545. View abstract
  6. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat Biotechnol. 2020 11; 38(11):1298-1308. View abstract
  7. Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response. Cell Stem Cell. 2019 04 04; 24(4):551-565.e8. View abstract
  8. Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell Stem Cell. 2018 12 06; 23(6):820-832.e9. View abstract
  9. Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients. EMBO Mol Med. 2017 11; 9(11):1574-1588. View abstract
  10. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci Transl Med. 2017 Oct 11; 9(411). View abstract
  11. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. Blood. 2017 08 03; 130(5):606-618. View abstract
  12. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition. Hum Gene Ther. 2015 Apr; 26(4):220-31. View abstract
  13. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014 Jun 12; 510(7504):235-240. View abstract
  14. Targeted gene therapy and cell reprogramming in Fanconi anemia. EMBO Mol Med. 2014 Jun; 6(6):835-48. View abstract
  15. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013 Nov 14; 122(20):3461-72. View abstract
  16. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012 May; 18(5):807-815. View abstract
  17. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods. 2011 Aug 21; 8(10):861-9. View abstract
  18. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol. 2011 Aug 07; 29(9):816-23. View abstract
  19. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology. 2011 May; 53(5):1696-707. View abstract
  20. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007 Nov; 25(11):1298-306. View abstract